| About the author: |
R. S. Vastyanov, O. S. Sadovyi, O. M. Stoyanov, V. V. Dobrovolskyi, O. V. Vastyanova, O. A. Gruzevskyi |
| Heading |
EXPERIMENTAL MEDICINE |
| Type of article |
Scentific article |
| Annotation |
Type 2 diabetes mellitus is becoming common disease and the most aggressive in terms of its onset in people of all ages. Understanding diabetes mellitus whole clinical picture complexity, associated primarily with its complications due to the complexity, cascade and versatility of “vicious circles” of disease pathogenetic mechanisms that cause both diabetic micro- and macroangiopathies formation, we attracted attention to the relationship ‘diabetes vs cognitive disorders’. Chronic experimental trials were performed on Wistar rats using the model of streptozotocin-induced experimental diabetes mellitus. To correct the mnestic disorders we used metformin and alpha-lipoic acid separate and combined administration. The data obtained indicate the formation of cognitive disorders in streptozotocin-induced experimental diabetes mellitus dynamics which is confirmed by learning process failure as well as short- and long-term memory weakening. We revealed a pronounced reduction of amnestic reactions in animals after metformin and alpha-lipoic acid combined administration, which is manifested by the investigated mnestic parameters normalization. The proposed complex scheme of pharmacocorrection is effective, has a pathogenetic basis and a pronounced sanogenetic effect, which in the case of further detailed study might have clinical significance. |
| Tags |
diabetes mellitus, training, short-term memory, long-term memory, conditioned reflexes, pathogenetic mechanisms, metformin, alpha-lipoic acid |
| Bibliography |
- Buresh Ya, Byreshova O, H'juston D. Metodiki i osnovnyie ekcnerimenty no izycheniyu mozga i povedeniya. Mоskva: Vyicshaya shkola, 1991: 400 [In Russian].
- Areosa Sastre A, Vernooij RW, Gonzalez-Colaco Harmand M, Martinez G. Effect of the treatment of Type 2 diabetes mellitus on the development of cognitive impairment and dementia. Cochrane Database Syst Rev. 2017; 6:CD003804. doi: 10.1002/14651858.CD003804.pub2
- Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2021. Diabetes Care. 2021; 44 (9): 15–33: doi: 10.2337/dc21-ad09
- Corrêa LBNS, da Costa CAS, Ribas JAS, Boaventura GT, Chagas MA. Antioxidant action of alpha lipoic acid on the testis and epididymis of diabetic rats: morphological, sperm and immunohistochemical evaluation. Int Braz J Urol. 2019; 45(4): 815–824. doi: 10.1590/S1677-5538.IBJU.2018.0774
- Daios S, Kaiafa G, Pilalas D, Nakou I, Kanellos I, Kirdas K, Despoudi K, Papanas N, Savopoulos C. Endothelial Dysfunction and Platelet Hyperaggregation in Type 2 Diabetes Mellitus: The Era of Novel Anti-diabetic Agents. Curr Med Chem. 2021; 28(20): 3935–3963. doi: 10.2174/0929867327666201009143816.
- El Midaoui A, Fantus IG, Ait Boughrous A, Couture R. Beneficial Effects of Alpha-Lipoic Acid on Hypertension, Visceral Obesity, UCP-1 Expression and Oxidative Stress in Zucker Diabetic Fatty Rats. Antioxidants (Basel). 2019; 8(12): 648. doi: 10.3390/antiox8120648.
- Hugo J, Ganguli M. Dementia and Cognitive Impairment: Epidemiology, Diagnosis, and Treatment. Clin Geriatr Med. 2014; 30(3): 421–442. doi:10.1016/j.cger.2014.04.001.
- International Diabetes Federation. IDF Diabetes Atlas. 8th ed. Brussels: IDF, 2017: 124
- Prince M, Bryce R, Albanese E, Wimo A, Ribeiro W, Ferri CP. The global prevalence of dementia: a systematic review and metaanalysis. Alzheimers Dement. 2013; 9: 63–75
- Vinik AI, Park TS, Stansberry KB, Pittenger GL. Diabetic neuropathies. Diabetologia. 2000; 43 (8): 957–973. DOI: 10.1007/s001250051477
- Wagner R, Heni M, Tabák AG, Machann J, Schick F, Randrianarisoa E, Hrabě de Angelis M, Birkenfeld AL, Stefan N, Peter A, Häring H-U, Fritsche A. Pathophysiology-based subphenotyping of individuals at elevated risk for type 2 diabetes. Nat Med. 2021; 27(1): 49–57. doi: 10.1038/s41591-020-1116-9.
- Wodschow HZ, Jensen NJ, Nilsson MSDD, Rungby J. The effect of hyper- and hypoglycaemia on cognition and development of dementia for patients with diabetes mellitus type 2. Ugeskr Laeger. 2018; 180(51):V08180566.
- Wu C-Y, Ouk M, Wong YY, Anita NZ, Edwards JD, Yang P, Shah BR, Herrmann N, Lanctôt KL, Kapral MK, MacIntosh BJ, Rabin JS, Black SE, Swardfager W. Relationships between memory decline and the use of metformin or DPP4 inhibitors in people with type 2 diabetes with normal cognition or Alzheimer's disease, and the role APOE carrier status. Alzheimers Dement. 2020; 16(12): 1663–1673. doi: 10.1002/alz.12161.
|
| Publication of the article |
«World of Medicine and Biology» №4(78), 2021 year, 203-208 pages, index UDK 616.379-008.64:611-018.74-092.9 |
| DOI |
10.26724/2079-8334-2021-4-78-203-208 |
